STOCK TITAN

[8-K/A] DocGo Inc. Amends Material Event Report

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
8-K/A
Rhea-AI Filing Summary

DocGo Inc. filed an amended Form 8‑K to attach the Merger Agreement for its completed acquisition of SteadyMD, Inc. via subsidiary Ambulnz Holdings, LLC. The transaction totals up to $25 million, consisting of $12.5 million in cash paid at closing and up to $12.5 million as a contingent earn‑out payable in cash or equity at the Company’s election, tied to performance conditions. The closing payment is subject to customary post‑closing adjustments for working capital, debt, and transaction expenses.

Upon filing a Certificate of Merger on October 20, 2025, SteadyMD merged into STMD Merger Company, LLC, which survived; all shares, options, and warrants of the Acquired Company were canceled. This amendment adds the Merger Agreement as Exhibit 2.1 and does not change other prior disclosures.

DocGo Inc. ha presentato un Modulo 8-K modificato per allegare l'Accordo di Fusione relativo alla sua acquisizione completata di SteadyMD, Inc. tramite la controllata Ambulnz Holdings, LLC. La transazione ammonta a $25 milioni, di cui $12,5 milioni in contanti pagati al closing e fino a $12,5 milioni come earn-out contingente pagabile in contanti o in equity a scelta della Società, legato a condizioni prestazionali. Il pagamento di chiusura è soggetto a consueti aggiustamenti post-chiusura per capitale circolante, debito e spese di transazione.

All'apertura dei registri di Fusione il 20 ottobre 2025, SteadyMD si è fusa in STMD Merger Company, LLC, che è sopravvissuta; tutte le azioni, opzioni e warrant della Società Acquisita sono stati annullati. Questa modifica aggiunge l'Accordo di Fusione come Allegato 2.1 e non modifica le altre dichiarazioni precedenti.

DocGo Inc. presentó un Formulario 8-K enmendado para adjuntar el Acuerdo de Fusión de su adquisición completada de SteadyMD, Inc. mediante la filial Ambulnz Holdings, LLC. La transacción asciende a $25 millones, consistente en $12,5 millones en efectivo pagados al cierre y hasta $12,5 millones como earn-out contingente pagadero en efectivo o en acciones a elección de la Compañía, ligado a condiciones de rendimiento. El pago de cierre está sujeto a ajustes posteriores al cierre por capital de trabajo, deuda y gastos de transacción.

Al presentar un Certificado de Fusión el 20 de octubre de 2025, SteadyMD se fusionó en STMD Merger Company, LLC, que sobrevivió; todas las acciones, opciones y warrants de la Sociedad Adquirida fueron cancelados. Esta enmienda añade el Acuerdo de Fusión como Anexo 2.1 y no modifica otras divulgaciones anteriores.

DocGo Inc. 은 완료된 인수에 대한 합병 계약서를 첨부하기 위해 개정된 Form 8‑K를 제출했고, SteadyMD, Inc.를 자회사 Ambulnz Holdings, LLC를 통해 인수하였습니다. 거래 규모는 총 $25 million이며, 그 중 클로징 시 현금으로 $12.5 million이 지급되고, 회사 선택에 따라 현금 또는 주식으로 지급되는 조건부 이익배당으로 최대 $12.5 million이 지급될 수 있습니다. 마감 시 지급액은 운전자본, 부채 및 거래비용에 대한 관례적 종가 조정의 대상입니다.

2025년 10월 20일에 합병 증서를 제출함에 따라 SteadyMD는 STMD Merger Company, LLC에 합병되어 존속했고, 피인수 회사의 모든 주식, 옵션 및 워런트는 취소되었습니다. 이 수정은 합병 계약서를 부록 2.1로 추가하고, 다른 사전 공시는 변경하지 않습니다.

DocGo Inc. a déposé un Formulaire 8-K modifié pour joindre l'Accord de Fusion relatif à son acquisition achevée de SteadyMD, Inc. par l'intermédiaire de la filiale Ambulnz Holdings, LLC. La transaction s'élève à $25 millions, comprenant $12,5 millions en espèces payés à la clôture et jusqu'à $12,5 millions en tant que earn-out conditionnel payable en espèces ou en actions au choix de la Société, lié à des conditions de performance. Le paiement à la clôture est soumis à des ajustements post-clôture habituels pour fonds de roulement, dette et frais de transaction.

Lors du dépôt d'un Certificat de Fusion le 20 octobre 2025, SteadyMD a fusionné dans STMD Merger Company, LLC, qui a survécu; toutes les actions, options et warrants de la Société Acquise ont été annulés. Cette modification ajoute l'Accord de Fusion en tant que Annexe 2.1 et ne modifie pas les autres divulgations antérieures.

DocGo Inc. hat ein geändertes Form 8-K eingereicht, um die Fusionsvereinbarung für den abgeschlossenen Erwerb von SteadyMD, Inc. über die Tochtergesellschaft Ambulnz Holdings, LLC beizufügen. Die Transaktion beläuft sich auf insgesamt $25 Millionen, davon $12,5 Millionen in bar zum Closing und bis zu $12,5 Millionen als contingenter Earn-out zahlbar in bar oder Eigenkapital nach Wahl des Unternehmens, gebunden an Leistungsbedingungen. Die Closing-Zahlung unterliegt üblichen post-closing Anpassungen für Working Capital, Schulden und Transaktionskosten.

Nach Einreichung eines Verschmelzungszertifikats am 20. Oktober 2025 fusionierte SteadyMD in die STMD Merger Company, LLC, die überlebte; alle Anteile, Optionen und Warrants der Übernommenen Gesellschaft wurden storniert. Diese Änderungen fügen die Fusionsvereinbarung als Anhang 2.1 hinzu und ändern sonstige frühere Offenlegungen nicht.

DocGo Inc. قدمت نموذج 8-K المعدل لإرفاق اتفاق الدمج لاكمال استحواذها على SteadyMD, Inc. عبر الشركة التابعة Ambulnz Holdings, LLC. تبلغ قيمة الصفقة الإجمالية حتى $25 مليون، وتتكون من $12.5 مليون نقدًا مدفوع عند الإغلاق و حتى $12.5 مليون ك earn-out مشروط يمكن أن يُدفع نقداً أو أسهماً وفق اختيار الشركة، مرتبط بشروط الأداء. الدفعة الإغلاقية تخضع لتعديلات الاغلاق المعتادة على رأس المال العامل، والديون، وتكاليف المعاملة.

عند تقديم شهادة الاندماج في 20 أكتوبر 2025، اندلعت SteadyMD في STMD Merger Company, LLC، التي نمت؛ تم إلغاء جميع الأسهم والخيارات والضمانات التابعة للشركة المستحوَذة. تُضيف هذه التعديل اتفاق الدمج كالمادة 2.1 وتلازم دون تغيير الإفصاءات الأخرى السابقة.

Positive
  • None.
Negative
  • None.

Insights

DocGo closed a bolt‑on deal up to $25M with an earn‑out.

DocGo, through Ambulnz, completed the SteadyMD acquisition on October 20, 2025 for up to $25 million. The consideration includes an upfront $12.5 million cash payment and an earn‑out of up to $12.5 million payable in cash or equity, contingent on performance.

The structure includes customary post‑closing purchase price adjustments and an indemnification framework for specified representations. The merger combined SteadyMD into STMD Merger Company, LLC, which remains as the surviving entity.

Cash impact at close is $12.5 million; any additional outlay depends on achieving performance conditions. Actual earn‑out realization and any working capital true‑ups will be determinable from subsequent disclosures.

DocGo Inc. ha presentato un Modulo 8-K modificato per allegare l'Accordo di Fusione relativo alla sua acquisizione completata di SteadyMD, Inc. tramite la controllata Ambulnz Holdings, LLC. La transazione ammonta a $25 milioni, di cui $12,5 milioni in contanti pagati al closing e fino a $12,5 milioni come earn-out contingente pagabile in contanti o in equity a scelta della Società, legato a condizioni prestazionali. Il pagamento di chiusura è soggetto a consueti aggiustamenti post-chiusura per capitale circolante, debito e spese di transazione.

All'apertura dei registri di Fusione il 20 ottobre 2025, SteadyMD si è fusa in STMD Merger Company, LLC, che è sopravvissuta; tutte le azioni, opzioni e warrant della Società Acquisita sono stati annullati. Questa modifica aggiunge l'Accordo di Fusione come Allegato 2.1 e non modifica le altre dichiarazioni precedenti.

DocGo Inc. presentó un Formulario 8-K enmendado para adjuntar el Acuerdo de Fusión de su adquisición completada de SteadyMD, Inc. mediante la filial Ambulnz Holdings, LLC. La transacción asciende a $25 millones, consistente en $12,5 millones en efectivo pagados al cierre y hasta $12,5 millones como earn-out contingente pagadero en efectivo o en acciones a elección de la Compañía, ligado a condiciones de rendimiento. El pago de cierre está sujeto a ajustes posteriores al cierre por capital de trabajo, deuda y gastos de transacción.

Al presentar un Certificado de Fusión el 20 de octubre de 2025, SteadyMD se fusionó en STMD Merger Company, LLC, que sobrevivió; todas las acciones, opciones y warrants de la Sociedad Adquirida fueron cancelados. Esta enmienda añade el Acuerdo de Fusión como Anexo 2.1 y no modifica otras divulgaciones anteriores.

DocGo Inc. 은 완료된 인수에 대한 합병 계약서를 첨부하기 위해 개정된 Form 8‑K를 제출했고, SteadyMD, Inc.를 자회사 Ambulnz Holdings, LLC를 통해 인수하였습니다. 거래 규모는 총 $25 million이며, 그 중 클로징 시 현금으로 $12.5 million이 지급되고, 회사 선택에 따라 현금 또는 주식으로 지급되는 조건부 이익배당으로 최대 $12.5 million이 지급될 수 있습니다. 마감 시 지급액은 운전자본, 부채 및 거래비용에 대한 관례적 종가 조정의 대상입니다.

2025년 10월 20일에 합병 증서를 제출함에 따라 SteadyMD는 STMD Merger Company, LLC에 합병되어 존속했고, 피인수 회사의 모든 주식, 옵션 및 워런트는 취소되었습니다. 이 수정은 합병 계약서를 부록 2.1로 추가하고, 다른 사전 공시는 변경하지 않습니다.

DocGo Inc. a déposé un Formulaire 8-K modifié pour joindre l'Accord de Fusion relatif à son acquisition achevée de SteadyMD, Inc. par l'intermédiaire de la filiale Ambulnz Holdings, LLC. La transaction s'élève à $25 millions, comprenant $12,5 millions en espèces payés à la clôture et jusqu'à $12,5 millions en tant que earn-out conditionnel payable en espèces ou en actions au choix de la Société, lié à des conditions de performance. Le paiement à la clôture est soumis à des ajustements post-clôture habituels pour fonds de roulement, dette et frais de transaction.

Lors du dépôt d'un Certificat de Fusion le 20 octobre 2025, SteadyMD a fusionné dans STMD Merger Company, LLC, qui a survécu; toutes les actions, options et warrants de la Société Acquise ont été annulés. Cette modification ajoute l'Accord de Fusion en tant que Annexe 2.1 et ne modifie pas les autres divulgations antérieures.

DocGo Inc. hat ein geändertes Form 8-K eingereicht, um die Fusionsvereinbarung für den abgeschlossenen Erwerb von SteadyMD, Inc. über die Tochtergesellschaft Ambulnz Holdings, LLC beizufügen. Die Transaktion beläuft sich auf insgesamt $25 Millionen, davon $12,5 Millionen in bar zum Closing und bis zu $12,5 Millionen als contingenter Earn-out zahlbar in bar oder Eigenkapital nach Wahl des Unternehmens, gebunden an Leistungsbedingungen. Die Closing-Zahlung unterliegt üblichen post-closing Anpassungen für Working Capital, Schulden und Transaktionskosten.

Nach Einreichung eines Verschmelzungszertifikats am 20. Oktober 2025 fusionierte SteadyMD in die STMD Merger Company, LLC, die überlebte; alle Anteile, Optionen und Warrants der Übernommenen Gesellschaft wurden storniert. Diese Änderungen fügen die Fusionsvereinbarung als Anhang 2.1 hinzu und ändern sonstige frühere Offenlegungen nicht.

true 0001822359 0001822359 2025-10-20 2025-10-20 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K/A
(Amendment No. 1)
 

 

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

 

Date of Report (date of earliest event reported): October 20, 2025

 

DOCGO INC.

(Exact name of registrant as specified in its charter)

 

Delaware   001-39618   85-2515483
(State or other jurisdiction of
incorporation or organization)
  (Commission File Number)   (I.R.S. Employer
Identification No.)

 

685 Third Avenue, 9th Floor, New York, New York   10017
(Address of principal executive offices)   (Zip Code)

 

(844) 443-6246
(Registrant’s telephone number, including area code)
 
N/A
(Former name or former address, if changed since last report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
   
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
   
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
   
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class   Trading Symbol   Name of each exchange on which registered
Common stock, par value $0.0001 per share   DCGO   The Nasdaq Stock Market LLC

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 12b-2 of the Exchange Act.

 

Emerging growth company  

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 

 

 

Explanatory Note

 

On October 20, 2025, DocGo Inc., a Delaware corporation, filed a Current Report on Form 8-K (the “Original 8-K”) disclosing its entry into a Merger Agreement (as defined below) with STMD Merger Company, LLC, a Delaware limited liability company, the Acquired Company (as defined below), and Shareholder Representative Services LLC, a Colorado limited liability company, solely in its capacity as the representative for the Indemnification Support Parties (as defined in the Merger Agreement), pursuant to which the Purchaser (as defined below) on October 20, 2025 has acquired the Acquired Company.

 

As disclosed in the Original 8-K, this Amendment No. 1 to the Original 8-K is being filed solely to include a copy of the Merger Agreement as Exhibit 2.1 to the Original 8-K. This Amendment No. 1 does not otherwise modify any other portions of the disclosure in the Original 8-K.

 

1

 

 

Item 1.01 Entry into a Material Definitive Agreement

 

On October 20, 2025, Ambulnz Holdings, LLC (the “Purchaser”), a Delaware limited liability company and wholly-owned subsidiary of DocGo Inc. (the “Company”), a Delaware corporation, entered into an Agreement and Plan of Merger (the “Merger Agreement”) with STMD Merger Company, LLC, a Delaware limited liability company (“MergerCo”), SteadyMD, Inc., a Delaware corporation (the “Acquired Company”), and Shareholder Representative Services LLC, a Colorado limited liability company, solely in its capacity as the representative for the Indemnification Support Parties (as defined in the Merger Agreement), pursuant to which the Purchaser on October 20, 2025 has acquired the Acquired Company (the “Transaction”) for an aggregate purchase price of up to $25 million, consisting of $12.5 million in cash payable at the closing of the Transaction (the “Closing Purchase Price”) and up to $12.5 million as a contingent earn-out payment, payable (in cash or equity, at the Company’s election) if certain performance conditions are met. The Closing Purchase Price is subject to a customary post-closing purchase price adjustment for working capital, indebtedness, transaction expenses and certain other items. Capitalized terms used herein and not otherwise defined herein have the meanings set forth in the Merger Agreement.

 

Pursuant to the Merger Agreement, upon the filing of a Certificate of Merger with the Secretary of State of the State of Delaware on October 20, 2025, the Acquired Company merged with and into MergerCo with MergerCo surviving. In connection with the Transaction, all Shares, Options, and Warrants were automatically cancelled (in each case, as defined in the Merger Agreement). The Merger Agreement contains customary representations and warranties and covenants of the Acquired Company and the Purchaser and the obligation of the Indemnification Support Parties to indemnify the Purchaser for a specified period of time for breaches of certain representations and warranties.

 

The foregoing description of the Merger Agreement and the transactions contemplated thereby does not purport to be complete and is subject to, and qualified in its entirety by, the full text of the Merger Agreement, a copy of which is filed as Exhibit 2.1 to this Current Report, as amended.

 

Item 9.01 Financial Statements and Exhibits.

 

(d) Exhibits

 

Exhibit No.   Description
2.1   Agreement and Plan of Merger, dated as of October 20, 2025, by and among Ambulnz Holdings, LLC, STMD Merger Company, LLC, SteadyMD, Inc. and Shareholder Representative Services LLC*
104   Cover Page Interactive Data File (formatted as Inline XBRL).

 

* Certain exhibits and schedules have been omitted pursuant to Item 601(a)(5) of Regulation S-K. The Company hereby undertakes to furnish supplemental copies of any of the omitted schedules upon request by the U.S. Securities and Exchange Commission; provided, that the Company may request confidential treatment pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended, for any schedules so furnished.

 

2

 

 

SIGNATURE

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

  DOCGO INC.
     
  By: /s/ Ely D. Tendler
  Name:  Ely D. Tendler
  Title: General Counsel and Secretary

 

Date: October 20, 2025

 

3

 

FAQ

What did DocGo (DCGO) announce in this 8-K/A?

DocGo filed an amendment to include the Merger Agreement as Exhibit 2.1 for its completed acquisition of SteadyMD.

What is the total purchase price for SteadyMD by DocGo (DCGO)?

The aggregate purchase price is up to $25 million.

How much cash did DocGo (DCGO) pay at closing for SteadyMD?

DocGo paid $12.5 million in cash at closing, subject to customary post‑closing adjustments.

Is there an earn‑out in the SteadyMD deal for DocGo (DCGO)?

Yes, up to $12.5 million as a contingent earn‑out payable in cash or equity at the Company’s election if performance conditions are met.

What legal structure was used to acquire SteadyMD?

SteadyMD merged into STMD Merger Company, LLC, which survived after the Certificate of Merger was filed on October 20, 2025.

Does this 8-K/A change earlier disclosures?

No. The amendment solely adds the Merger Agreement as an exhibit and does not modify prior disclosure.
DOCGO INC

NASDAQ:DCGO

DCGO Rankings

DCGO Latest News

DCGO Latest SEC Filings

DCGO Stock Data

123.24M
90.66M
7.31%
52.38%
4.13%
Medical Care Facilities
Services-health Services
Link
United States
NEW YORK